Winston-Salem, North Carolina 27157


Purpose:

This pilot clinical trial will examine the effects of intranasal insulin aspart on cognition, daily function, blood and cerebral spinal fluid markers of Alzheimer's disease, and amyloid deposition in the brain. Participants will be randomly assigned to receive insulin aspart or placebo during a 12-week treatment period.


Study summary:

A growing body of evidence suggests that insulin plays a role in normal memory processes and that insulin abnormalities may contribute to cognitive and brain changes associated with Alzheimer's disease (AD). Interestingly, insulin administered to the nasal cavity is transported within a few minutes into the brain, but does not affect blood sugar or insulin levels. This trial will consist of a randomized double-blind, placebo-controlled parallel group trial in which 30 participants with AD or mild cognitive impairment (MCI) receive twice daily intranasal administrations of insulin aspart (20 IU) or placebo (saline), two times per day for 12 weeks. All participants will appoint a "support person" to answer a collateral questionnaire and supervise the administration of the study drug. All participants and study partners will undergo the intensive, structured training program in the self-management of intranasal insulin administration. Cognitive testing and blood collection will occur at baseline, after 6 weeks of treatment, and at the end of the 12 week treatment period. Participants will also receive a lumbar puncture to measure AD biomarkers in the subject's cerebral spinal fluid.


Criteria:

Inclusion Criteria: - Previous or subsequent diagnosis of Alzheimer's disease or mild cognitive impairment - Ability to communicate in English Exclusion Criteria: - Preexisting diabetes - Clinically significant elevations in liver function test - Clinically significant elevations in lipid profile - Prior lumbar lumbar surgeries or other medical conditions that render lumbar punctures unsafe - Hemoglobin <8 g/dl - Significant neurologic disease that might affect cognition, other than Alzheimer's disease, including stroke, Parkinson's disease, multiple sclerosis, or recent severe head injury (within the last year) with loss of consciousness >30 minutes or with permanent neurologic sequelae - Significant medical illness or organ failure, such as uncontrolled hypertension or cardiovascular disease, chronic obstructive pulmonary disease, liver disease, or kidney disease - Current use of antipsychotic, anticonvulsant, anxiolytic, anticoagulant or sedative medications - Current or previous use of glucose-lowering agents or insulin; - Chronic use (≥ 3 times per week) of nasal sprays of any type for any indication - Premenopausal status (defined as having had a period within the last year).


NCT ID:

NCT02462161


Primary Contact:

Principal Investigator
Suzanne Craft, PhD
Wake Forest University Health Sciences

Deborah Dahl, RN
Phone: 336-713-3432
Email: ddahl@wakehealth.edu


Backup Contact:

N/A


Location Contact:

Winston-Salem, North Carolina 27157
United States

Deborah Dahl
Phone: 336-713-3432
Email: ddahl@wakehealth.edu

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: November 22, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.